AK
AKTS.US Aktis Oncology, Inc. Common stock
- Market cap
- USD 924M
- P/E
- -
- P/B
- 1.87x
- ROE
- -21.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AKTS.US undervalued?
Graham numberThe Graham number of Aktis Oncology, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aktis Oncology, Inc. Common stock fundamental analysis
No fundamental analysis for Aktis Oncology, Inc. Common stock yet.
Aktis Oncology, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colore…
Full company profileAktis Oncology, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aktis Oncology, Inc. Common stock annual financial statements
| Item | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 255K | 17.0K | 1.21M | 1.44M | 1.79M | 15.4M | 0.00 | 27.1M | 1.49M | 6.50M | 14.0M |
| Gross Profit | 226K | -93.1K | 188K | 430K | -624K | -4.14M | - | -3.12M | 1.49M | 6.50M | 10.7M |
| Operating Income | -4.69M | -9.96M | -22.3M | -27.5M | -32.0M | -60.6M | -19.8M | -34.8M | -52.1M | -74.7M | -115M |
| EBITDA | -3.87M | -10.6M | -20.6M | -25.1M | -29.0M | -52.8M | -17.5M | -27.5M | -42.4M | -61.4M | -107M |
| Net Income | -5.41M | -9.11M | -21.7M | -30.9M | -40.9M | -59.2M | -17.9M | -28.6M | -44.0M | -63.7M | -96.5M |
| EPS | -0.40 | -0.54 | -1.04 | -1.12 | -1.21 | -1.10 | -0.51 | -0.82 | -1.26 | -1.21 | -1.73 |
| Balance Sheet | |||||||||||
| Total Assets | 4.54M | 18.1M | 29.3M | 47.9M | 71.4M | 161M | 138M | 122M | 326M | 265M | 532M |
| Total Liabilities | 1.87M | 3.08M | 15.5M | 22.0M | 29.9M | 57.9M | 158M | 169M | 414M | 411M | 73.6M |
| Shareholders' Equity | 2.68M | 15.0M | 13.8M | 26.0M | 41.5M | 103M | -19.2M | -46.3M | -87.8M | -146M | 459M |
| Cash & Short-term Investments | 4.16M | 9.63M | 14.8M | 30.2M | 44.3M | 80.5M | 129M | 97.9M | 297M | 227M | 493M |
| Total Debt | - | - | 11.5M | 18.2M | 23.9M | 44.9M | 1.78M | 13.4M | 12.0M | 11.5M | 10.8M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.10M | -5.55M | -14.2M | -17.7M | -21.3M | -45.2M | -18.1M | -30.0M | 14.8M | -64.1M | -94.5M |
| Capital Expenditure | 47.2K | 1.69M | 7.01M | 4.92M | 9.95M | 27.7M | 2.31M | 3.76M | 2.86M | 9.58M | 5.18M |
| Free Cash Flow | -1.15M | -7.23M | -21.2M | -22.6M | -31.3M | -72.9M | -20.4M | -33.8M | 11.9M | -73.7M | -99.7M |
| Ratios | |||||||||||
| ROE | -202.0% | -60.7% | -157.0% | -119.0% | -98.5% | -57.2% | - | - | - | - | -21.0% |
| ROA | -119.0% | -50.3% | -74.2% | -64.4% | -57.2% | -36.7% | -13.0% | -23.4% | -13.5% | -24.1% | -18.1% |
| Net Profit Margin | -2,121.4% | -53,691.6% | -1,799.8% | -2,139.9% | -2,283.1% | -385.6% | - | -105.6% | -2,957.6% | -980.9% | -688.6% |
| Debt to Equity | - | - | 0.83x | 0.70x | 0.58x | 0.43x | - | - | - | - | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aktis Oncology, Inc. Common stock dividends
Aktis Oncology, Inc. Common stock has not paid dividends in the last 9 fiscal years.
Who owns Aktis Oncology, Inc. Common stock
- Insiders 14.21%
- Institutions 78.10%
- Public & others 7.69%
- Shares outstanding 53.7M
- Free float 28.7M
Top funds holding AKTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 1.46M | 2.63% | -25.14% | Sep 2026 |
| T. Rowe Price Small-Cap Stock | 1.18M | 2.13% | -0.57% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 854K | 1.53% | +45.90% | Sep 2026 |
| iShares Russell 2000 ETF | 711K | 1.28% | 0.00% | Oct 2026 |
| T. Rowe Price Health Sciences | 694K | 1.25% | 0.00% | Sep 2026 |
| T. Rowe Price Instl Small-Cap Stock | 638K | 1.15% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 547K | 0.98% | +2.69% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 507K | 0.91% | 0.00% | Jun 2026 |
| BGF World Healthscience A2 | 373K | 0.67% | 0.00% | Jul 2026 |
| Fidelity Select Biotechnology | 283K | 0.51% | 0.00% | Aug 2026 |
| BlackRock Health Sciences Opps Inv A | 267K | 0.48% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 232K | 0.42% | 0.00% | Aug 2026 |
| T. Rowe Price Small-Cap Value | 224K | 0.40% | 0.00% | Sep 2026 |
| T. Rowe Price US Smlr Coms Eq A | 209K | 0.38% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 184K | 0.33% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 166K | 0.30% | +36.30% | Sep 2026 |
| T. Rowe Price New Horizons | 159K | 0.29% | -11.03% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 135K | 0.24% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 122K | 0.22% | +30.99% | Sep 2026 |
| TD Health Sciences - I | 88.5K | 0.16% | 0.00% | Jun 2026 |
Top institutions holding AKTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| MPM Oncology Impact Management LP | 4.84M | 8.69% | 0.00% | Jun 2026 |
| EcoR1 Capital, LLC | 4.82M | 8.67% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 3.07M | 5.52% | -2.88% | Jun 2026 |
| BlackRock Inc | 2.28M | 4.10% | +7.87% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.05M | 3.69% | -3.41% | Jun 2026 |
| Wellington Management Company LLP | 1.97M | 3.54% | -15.14% | Jun 2026 |
| RTW INVESTMENTS, LLC | 1.59M | 2.86% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 1.31M | 2.36% | -12.55% | Jun 2026 |
| Jupiter Topco LLC | 1.31M | 2.36% | 0.00% | Jun 2026 |
| Baker Bros Advisors LP | 996K | 1.79% | 0.00% | Jun 2026 |
| Octagon Capital Advisors LP | 961K | 1.73% | 0.00% | Jun 2026 |
| Merck & Co Inc | 953K | 1.71% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 817K | 1.47% | -2.02% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 763K | 1.37% | -51.19% | Jun 2026 |
| TCG Crossover Management, LLC | 697K | 1.25% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 521K | 0.94% | +5.85% | Jun 2026 |
| Eventide Asset Management, LLC | 507K | 0.91% | 0.00% | Jun 2026 |
| Avidity Partners Management LP | 484K | 0.87% | -48.33% | Jun 2026 |
| State Street Corp | 484K | 0.87% | +13.02% | Jun 2026 |
| Alyeska Investment Group, L.P. | 290K | 0.52% | 0.00% | Jun 2026 |
Aktis Oncology, Inc. Common stock company profile
- Company name
- Aktis Oncology, Inc. Common stock
- Ticker
- AKTS.US
- Exchange
- USA Stocks
- Listed since
- Jan 9, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 79
- Fiscal year end
- December
- Address
- 17 Drydock Avenue, Boston, MA, United States, 02210
- Phone
- 617 461 4023
- Website
- aktisoncology.com
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Aktis Oncology, Inc. Common stock management
10- Mr. Todd Foley M.B.A.Co-Founder & Chairman · born 1972
- Dr. Matthew Roden Ph.D.President, CEO & Director
- Dr. Paul L. Feldman Ph.D.Chief Scientific Officer · born 1962
- Dr. Akos Czibere M.D., Ph.D.Chief Medical Officer · born 1978
- Dr. Patrick A. Baeuerle Ph.D.Co-Founder & Member of Scientific Advisory Board · born 1958
- Mr. Kyle D. KuvalankaChief Financial Officer · born 1968
- Dr. Shulamit Ron-Bigger Ph.D.Chief Operating Officer · born 1981
- Dr. Tyler Benedum Ph.D.Chief Technical Officer · born 1977
- Mr. Carlos RodriguezExecutive Director of Corporate Development
- Dr. Dasa Lipovsek Ph.D.VP & Head of Lead Discovery